Wake Forest's largest study will examine whether weight control can slow hardening of the arteries in diabetics

October 04, 1999

WINSTON-SALEM, N.C. -- A major seven-year national study on whether weight control can slow the advance of heart disease in persons with diabetes will be headquartered at Wake Forest University School of Medicine, under a $40.6 million grant from the National Institute of Diabetes and Digestive and Kidney Disorders.

The grant, by far the largest in the school's history, includes funds to pay for 15 clinics across the country. No clinics will be located in Winston-Salem.

Mark Espeland, Ph.D., professor of public health sciences (biostatistics), will be principal investigator of the national coordinating center of the Study of Health Outcomes of Weight loss (SHOW).

The SHOW trial will involve 6,000 obese people who have adult-onset (type 2) diabetes, and test whether weight loss will reduce the adverse health problems commonly encountered by diabetics, especially cardiovascular disease.

"Weight loss is associated with improvements in numerous cardiovascular disease risk factors, including decreased LDL cholesterol [the bad cholesterol], reduced blood pressure, decreased blood glucose levels and improved insulin sensitivity," Espeland said.

But he said he knew of no studies that directly measure whether weight loss slows progression of atherosclerosis. "SHOW will be the first large trial designed in a manner to measure this."

Each of the 15 centers will enroll about 400 participants. They will be assigned randomly to community care or interventions aimed at reducing daily food consumption, reducing dietary fat and increasing physical activity each week. A weight-loss drug may be used by participants for whom weight loss is more difficult.

Experts in nutrition, exercise and behavior change from across the country will design these interventions so they will be effective, safe and appropriate for women and men of different ages and cultural groups. After the design is complete, recruiting of patients will begin, probably in late 2000 or early 2001.

Participants in the community-care arm will receive medical care from their personal physicians. They will also receive SHOW mailings and be invited to regular education sessions on diabetes-related subjects -- except weight control.

Ultrasound will be used to measure the thickness of carotid artery walls to gauge the buildup of atherosclerosis -- hardening of the arteries -- and will be a key measure on whether the weight reduction program is having an effect.

For more than a decade, Wake Forest University has been a world leader in using carotid ultrasound to measure the pace of advancing atherosclerosis and developing statistical methods to interpret these data.

In the study, the researchers will keep track of all heart attacks and strokes in the groups as well as recording deaths from all causes. And they'll be looking at how well weight loss leads to a reduction in other cardiovascular risk factors and whether it leads to reduction or elimination of oral diabetes drugs.

Lynne E. Wagenknecht, Dr. P.H., associate professor of public health sciences (epidemiology), one of the project co-directors, has been instrumental is demonstrating the increased risks of atherosclerosis borne by people with diabetes

Wagenknecht said that the reasons why diabetes accelerates the risk of heart disease are not fully understood. One explanation is that diabetics have a number of adverse risk factors including obesity. "This study could have an important impact on the 15 million diabetics in the United States, nearly half of whom are overweight."

The study results from close collaboration between Wake Forest's Bowman Gray and Reynolda campuses. Investigators from four departments -- seven academic units -- make up the study team.. Besides Wagenknecht, co-directors are David M. Reboussin, Ph.D., associate professor of public health sciences (biostatistics), W. Jack Rejeski, professor of health and exercise sciences, and Judy Bahnson, research associate.
-end-


Wake Forest Baptist Medical Center

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.